2012 ASN Update on Patient Centered Outcomes Research in Kidney Disease
2012 ASN Update on Patient Centered Outcomes Research in Kidney Disease
批准号:
8458852
负责人:
WOLFGANG CHRISTOPH WINKELMAYER
金额:
$1.0万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-09-05 至 2013-08-31
关键词:
AllyAmericanApplications GrantsAreaAwardAwarenessBasic ScienceBehavioral ResearchBioinformaticsBiometryCardiovascular DiseasesClinicalClinical ResearchClinical SciencesCollaborationsCommunicationCommunitiesCommunity HealthComorbidityDataData SetDecision MakingDisease OutcomeEducationEnsureEpidemiologistEpidemiologyFaceFacultyFundingGoalsGraduate EducationGrantHealth ProfessionalHealth ServicesHealth Services ResearchIndividualInvestigationKidneyKidney DiseasesLeadLinkMedicareMinorityNephrologyOutcomes ResearchParticipantPatient-Focused OutcomesPatientsPharmaceutical PreparationsPhysiciansPopulationPostdoctoral FellowProcessProviderPublic HealthReportingResearchResearch DesignResearch InstituteResearch PersonnelResourcesScientistSeriesSocietiesTechniquesTherapeuticTimeTranslational ResearchTravelUnderrepresented MinorityUnited States National Institutes of HealthUpdateWomanWorkcareerclinical decision-makingcomparativecomparative effectivenesscostcost effectivedesigndisabilityeffectiveness researchexperiencegraduate studenthealth care qualityimprovedinnovationinterestlecturesmeetingsmemberpatient orientedpatient populationpolicy implicationpopulation healthpreferenceracial and ethnicresearch studysocioeconomicssymposium
中文摘要
描述(由申请人提供):美国肾脏病学会(ASN)的年度会议,“肾脏周”,是世界上最大的临床、转化和基础科学研究人员在肾脏病领域工作的聚会。在肾脏周的前两天,ASN赞助了一系列密集的专题讨论会,包括为期两天的年度临床研究教育研讨会,参与者包括临床医生调查员、研究生、博士后研究员、职业生涯早期到中期的院士、执业医生和联合医疗保健专业人员。本次研讨会的主题领域由ASN的研究生教育(PGE)委员会全面审查,反映了重要的和时间敏感的临床和转化研究领域,对肾脏疾病及其相关合并症和并发症的管理具有重要的临床和公共卫生意义。今年的研讨会将以“以患者为中心的肾脏疾病结果研究的最新进展”为主题,并将于2012年10月30日至31日在加州圣地亚哥会议中心举行的ASN肾脏周期间举行。研讨会将由27位该领域的领导者进行演讲,其中大多数是公认的世界级专家,他们将从设计和实施以患者为中心的研究的各个方面发言。所涵盖的主题将包括“以患者为中心”的重要方面,以及将不同利益相关者群体的投入和偏好纳入研究过程各个方面的策略,并特别强调在此类研究中要考虑的种族,民族和社会经济差异方面。本课程还将提供以患者为中心的结果研究的现有数据集的详细信息,特别强调最近通过USRDS可用于研究的医疗保险D部分药物数据。目前使用这些数据集的科学家将讨论他们使用这些数据资源的实际经验。第二天将重点关注研究设计的重要考虑因素,一系列传统的高度创新的分析技术,以及以患者为中心的结果研究结果的适当沟通和报告。所选主题完全符合美国国立卫生研究院的路线图,以及医疗保健研究和质量机构(AHRQ)和以患者为中心的结果研究所(PCORI)的目标,即促进对社区健康产生直接影响的临床和转化研究。在这次会议上,ASN成员和其他感兴趣的参与者将有机会与该领域的世界领导人进行互动。本资助申请的目的是为初级教师和早期职业研究者、博士后研究员和研究生申请旅行奖励,以便他们能够在今年肾脏周的前两天参加本次会议。在计划委员会和特邀教员中,少数民族和妇女的代表人数都很高,并且计划资助代表性不足的少数民族申请人和妇女以及残疾人参加旅行补助金和其他活动。
英文摘要
DESCRIPTION (provided by applicant): The annual meeting of the American Society of Nephrology (ASN), "Kidney Week," is the largest gathering in the world of clinical, translational and basic science investigators working in the field of nephrology. During the first two days of Kidney Week, the ASN sponsors a series of intensive symposia including an annual 2-day educational clinical research symposium for clinician investigators, graduate students, post- doctoral fellows, early- to mid-career academicians, practicing physicians and allied health care professionals. The subject area of this symposium is reviewed thoroughly by the ASN's Post-Graduate Education (PGE) Committee and reflects important and time-sensitive areas of clinical and translational investigation with important clinical and public health implications for the management of kidney diseases and their related comorbidities and complications. This year's symposium will be titled "Update on Patient-Centered Outcomes Research in Kidney Disease" and held during the upcoming ASN Kidney Week on 10/30-31, 2012, at the San Diego Convention Center, San Diego, CA. The symposium will feature lectures by 27 leaders in the field, most recognized as world class experts who will speak on diverse aspects of design and conduct of patient-centered studies. The topics covered will include sessions on the important aspect of "patient-centeredness," on strategies to incorporate the input and preferences of diverse groups of stakeholders into all aspects of the research process, and particular emphasis will be put on aspects of racial, ethnic, and socioeconomic disparities to be considered in such research. The course will also provide detailed information on existing datasets for Patient-Centered Outcomes Research with particular emphasis on Medicare Part D medication data that have just recently become available for research through the USRDS. Scientists currently using these datasets will discuss their hands-on experiences with these data resources. Day 2 will focus on important considerations about study design, a range of traditional to highly innovative analytical techniques, and the appropriate communication and reporting of findings from Patient-Centered Outcomes Research studies. The selected topics are fully consistent with the NIH roadmap as well as the objectives of the Agency for Healthcare Research and Quality (AHRQ) and the Patient-Centered Outcomes Research Institute (PCORI) to promote clinical and translational research with immediate impact on community health. At this conference, ASN members and other interested participants will have the chance to interact with world leaders in the field. The purpose of this grant application is to request funds for travl awards for junior faculty and early career investigators, postdoctoral fellows, and graduate students, so that they can attend this conference during the first 2 days of this year's Kidney Week. Individuals from minorities and women are well represented among both planning committee and invited faculty members, and there are plans to sponsor underrepresented minority applicants and women as well as individuals with disabilities for the travel grants and other activities.
PUBLIC HEALTH RELEVANCE: The goal of this annual conference is to improve education and awareness of the kidney disease community about the importance of clinical research with immediate impact on improving kidney disease outcomes in the community. The focus of this year's conference is to update the clinician investigators about the design and conduct of "Patient Centered Outcomes Research," which is research that directly informs decisions that patients and providers face among on comparative strategies in real world practice settings of largely unrestricted populations of patients. In the past, conference participants have developed collaborative relationships with some of the faculty speakers, which greatly helps advance kidney disease research and the potential to develop therapeutic strategies that may serve to improve the health of the population.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Atrial Fibrillation-Factor Identification to Risk Modification Study in CKD/ESRD
-
批准号:10542356
-
项目类别:
-
资助金额:$51.56万
-
财政年份:2012
-
负责人:WOLFGANG CHRISTOPH WINKELMAYER
-
依托单位:
The Atrial Fibrillation - Factor Identification to Risk Modification Study in HD
-
批准号:8372215
-
项目类别:
-
资助金额:$50.42万
-
财政年份:2012
-
负责人:WOLFGANG CHRISTOPH WINKELMAYER
-
依托单位:
The Atrial Fibrillation - Factor Identification to Risk Modification Study in HD
-
批准号:8678908
-
项目类别:
-
资助金额:$46.56万
-
财政年份:2012
-
负责人:WOLFGANG CHRISTOPH WINKELMAYER
-
依托单位:
The Atrial Fibrillation-Factor Identification to Risk Modification Study in CKD/ESRD
-
批准号:10084289
-
项目类别:
-
资助金额:$68.85万
-
财政年份:2012
-
负责人:WOLFGANG CHRISTOPH WINKELMAYER
-
依托单位:
The Atrial Fibrillation-Factor Identification to Risk Modification Study in CKD/ESRD
-
批准号:10319987
-
项目类别:
-
资助金额:$52.53万
-
财政年份:2012
-
负责人:WOLFGANG CHRISTOPH WINKELMAYER
-
依托单位:
The Atrial Fibrillation-Factor Identification to Risk Modification Study in CKD/ESRD
-
批准号:9885396
-
项目类别:
-
资助金额:$64.87万
-
财政年份:2012
-
负责人:WOLFGANG CHRISTOPH WINKELMAYER
-
依托单位:
The Atrial Fibrillation - Factor Identification to Risk Modification Study in HD
-
批准号:8517713
-
项目类别:
-
资助金额:$46.27万
-
财政年份:2012
-
负责人:WOLFGANG CHRISTOPH WINKELMAYER
-
依托单位:
Comparative Effectiveness and Safety of Newer Agents for Anemia Treatment in HD
-
批准号:8238024
-
项目类别:
-
资助金额:$50.19万
-
财政年份:2011
-
负责人:WOLFGANG CHRISTOPH WINKELMAYER
-
依托单位:
Comparative Effectiveness and Safety of Newer Agents for Anemia Treatment in HD
-
批准号:8540416
-
项目类别:
-
资助金额:$8.29万
-
财政年份:2011
-
负责人:WOLFGANG CHRISTOPH WINKELMAYER
-
依托单位:
Comparative Effectiveness and Safety of Newer Agents for Anemia Treatment in HD
-
批准号:8335495
-
项目类别:
-
资助金额:$41.31万
-
财政年份:2011
-
负责人:WOLFGANG CHRISTOPH WINKELMAYER
-
依托单位:
Comparative Effectiveness and Safety of Newer Agents for Anemia Treatment in HD
-
批准号:9038583
-
项目类别:
-
资助金额:$33.16万
-
财政年份:2011
-
负责人:WOLFGANG CHRISTOPH WINKELMAYER
-
依托单位:
Warfarin Use in ESRD Patients with Atrial Fibrillation: Risks, Benefits, Behavior
-
批准号:7589083
-
项目类别:
-
资助金额:$26.63万
-
财政年份:2009
-
负责人:WOLFGANG CHRISTOPH WINKELMAYER
-
依托单位:
Warfarin Use in ESRD Patients with Atrial Fibrillation: Risks, Benefits, Behavior
-
批准号:7896845
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2009
-
负责人:WOLFGANG CHRISTOPH WINKELMAYER
-
依托单位:
海外基金